This article is for informational purposes only and does not constitute medical advice
What's most exciting isn't just the market performance of these companiesit's the impact their innovations are having on patients facing some of the most challenging diseases and conditions
The expiration of patents in 2028 may open the door for biosimilars, but the formidable barriers in the field of oncology for Pembrolizumab (Keytruda) are not easily shaken
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
What drugmakers are arguing about now is what kind of weight comes off, whether patients are losing fat or muscle, and what other benefits could be gained from these drugs
The FDA and EMA approvals of ZepBound in late 2023 and early 2024 (for weight management) were major regulatory milestones achieved by Lilly ahead of many competitors
